TWI859506B - 化合物組合用於製作血管疾病治療藥的用途 - Google Patents
化合物組合用於製作血管疾病治療藥的用途 Download PDFInfo
- Publication number
- TWI859506B TWI859506B TW111104639A TW111104639A TWI859506B TW I859506 B TWI859506 B TW I859506B TW 111104639 A TW111104639 A TW 111104639A TW 111104639 A TW111104639 A TW 111104639A TW I859506 B TWI859506 B TW I859506B
- Authority
- TW
- Taiwan
- Prior art keywords
- sildenafil
- vascular
- compound combination
- treatment
- sild
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW111104639A TWI859506B (zh) | 2022-02-09 | 2022-02-09 | 化合物組合用於製作血管疾病治療藥的用途 |
| JP2024547249A JP2025504219A (ja) | 2022-02-09 | 2023-02-09 | Pde5阻害剤、アルギニン、及びn-アセチルシステインを含む、血管疾患を治療するための化合物の組合せ |
| CN202310100652.1A CN116808224A (zh) | 2022-02-09 | 2023-02-09 | 用于治疗血管疾病的化合物组合 |
| KR1020247028842A KR20240146018A (ko) | 2022-02-09 | 2023-02-09 | Pde5 억제제, 아르기닌 및 n-아세틸시스테인을 포함하는 혈관 질병 치료를 위한 화합물의 병용 |
| EP23706081.9A EP4475833A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
| PCT/GB2023/050296 WO2023152500A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
| US18/836,532 US20250134892A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
| AU2023219232A AU2023219232A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW111104639A TWI859506B (zh) | 2022-02-09 | 2022-02-09 | 化合物組合用於製作血管疾病治療藥的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202332450A TW202332450A (zh) | 2023-08-16 |
| TWI859506B true TWI859506B (zh) | 2024-10-21 |
Family
ID=85283927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111104639A TWI859506B (zh) | 2022-02-09 | 2022-02-09 | 化合物組合用於製作血管疾病治療藥的用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134892A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4475833A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025504219A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240146018A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116808224A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023219232A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI859506B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023152500A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI879058B (zh) * | 2023-08-31 | 2025-04-01 | 未來新藥股份有限公司 | Pde5抑制劑組合於促進神經突生長之新穎用途 |
| CN122055146A (zh) * | 2023-08-31 | 2026-05-15 | 未来新药股份有限公司 | Pde5抑制剂组合于促进神经突生长的新颖用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000000212A1 (en) | 1998-06-26 | 2000-01-06 | Nutracorp Scientific, Inc. | Promoting nitric oxide and cyclic gmp activity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL132460A0 (en) * | 1999-10-19 | 2001-03-19 | Laniado Shlomo | Sildenafil preparation |
-
2022
- 2022-02-09 TW TW111104639A patent/TWI859506B/zh active
-
2023
- 2023-02-09 WO PCT/GB2023/050296 patent/WO2023152500A1/en not_active Ceased
- 2023-02-09 CN CN202310100652.1A patent/CN116808224A/zh active Pending
- 2023-02-09 US US18/836,532 patent/US20250134892A1/en active Pending
- 2023-02-09 JP JP2024547249A patent/JP2025504219A/ja active Pending
- 2023-02-09 KR KR1020247028842A patent/KR20240146018A/ko active Pending
- 2023-02-09 AU AU2023219232A patent/AU2023219232A1/en active Pending
- 2023-02-09 EP EP23706081.9A patent/EP4475833A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000000212A1 (en) | 1998-06-26 | 2000-01-06 | Nutracorp Scientific, Inc. | Promoting nitric oxide and cyclic gmp activity |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Ruipeng Zhang,et al "N-Acetylcysteine potentiates the haemodynamic-improving effect of sildenafil in a rabbit model of acute pulmonary thromboembolism via the p38 MAPK pathway", Clin Exp Pharmacol Physiol, 46(2): 163-172, 2019 Feb. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116808224A (zh) | 2023-09-29 |
| US20250134892A1 (en) | 2025-05-01 |
| TW202332450A (zh) | 2023-08-16 |
| EP4475833A1 (en) | 2024-12-18 |
| KR20240146018A (ko) | 2024-10-07 |
| WO2023152500A1 (en) | 2023-08-17 |
| AU2023219232A1 (en) | 2024-07-25 |
| JP2025504219A (ja) | 2025-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bywaters et al. | Crush injuries with impairment of renal function | |
| Schurr et al. | Blockade of lactate transport exacerbates delayed neuronal damage in a rat model of cerebral ischemia | |
| Sánchez-Lozada et al. | Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia | |
| Mehanna et al. | An optimized dose of raspberry ketones controls hyperlipidemia and insulin resistance in male obese rats: Effect on adipose tissue expression of adipocytokines and Aquaporin 7 | |
| JP2001526658A (ja) | 虚血の治療および/または予防を行う際の医薬組成物の使用 | |
| TW202332450A (zh) | 化合物組合用於製作血管疾病治療藥的用途 | |
| Dinc et al. | Methylene blue inhibits the inflammatory process of the acetic acid-induced colitis in rat colonic mucosa | |
| Hanrahan et al. | A randomized, placebo‐controlled, multiple‐ascending‐dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the soluble guanylate cyclase stimulator praliciguat in healthy subjects | |
| Zhang et al. | GSK-3β inhibition elicits a neuroprotection by restoring lysosomal dysfunction in neurons via facilitation of TFEB nuclear translocation after ischemic stroke | |
| Sorensen et al. | Clinical evaluation of benzbromarone. A new uricosuric drug | |
| Benigni et al. | Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model | |
| Hedayati et al. | Growth hormone–releasing peptide ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells | |
| Moustafa et al. | Sildenafil citrate protects against gastric mucosal damage induced by indomethacin in rats. | |
| Mendel et al. | Pharmacology management in improving exercise capacity of patients with Fontan circulation: a systematic review and meta-analysis | |
| Kumar et al. | Intravenous sildenafil citrate and post-cardiac surgery acute kidney injury: a double-blind, randomised, placebo-controlled trial | |
| Ko et al. | Therapeutic hypothermia protects against heat stroke-induced arterial hypotension via promoting left ventricular performance in rats | |
| Liu et al. | Protective effect of crocin on liver function and survival in rats with traumatic hemorrhagic shock | |
| JP2020525511A (ja) | 低濃度のキセノンおよびアルゴンを含有するガス混合物は血栓溶解剤の触媒活性を阻害することなく神経保護を提供する | |
| GB2600668A (en) | Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection. | |
| Gruber et al. | Protracted metabolic acidosis: the impact of acute ethanol in hemorrhagic shock | |
| Harada et al. | Role of neutrophil elastase in development of pulmonary vascular injury and septic shock in rats | |
| Kirkeb⊘ en et al. | Importance of nitric oxide in canine femoral circulation: comparison of two NO inhibitors | |
| TWI907160B (zh) | 具有護腎功效的咪唑二肽組合物及其應用 | |
| Yu et al. | Protective Effect of Sufentanil against Myocardial Ischemia Reperfusion Injury in Rats | |
| Liu et al. | Cavernosum smooth muscle relaxation induced by Schisandrol A via the NO-cGMP signaling pathway |